1ANZ Heart Failure Research Collaborative Group.Randomized placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease[].The Lancet.1997
2Ma XL,Yue TL,Lopez B1,et al.Carvedilol, a new beta adrenoceptor blocker and free radical scavenger,attenuates myocardial ischemic-reperfusion injury in hyperchojesterolemic rabbits[].Journal of Pharmacology and Experimental Therapeutics.1996
3Yue TL,Wang X,Gu Jl,et al.Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibs oxidation of low density lipoproteins byvascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells[].Journal of Pharmacology and Experimental Therapeutics.1995
4Ohlstein EH,Douglas SA,Sung CP,et al.Carvedilol,a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury[].Proceedings of the National Academy of Sciences of the United States of America.1993
5Colucci WS,Packer M,Bristow MR,et al.Carvedilol inhibits clinical progression in patients with symptoms of heart failure[].Circulation.1996
6McTavish D,Campoli Richards D,Sorkin EM.Carvedi lol, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy[].Drugs.1993
7Brunvand H,Kvitting PM,Rynning SE,et al.Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms[].Journal of Cardiovascular Pharmacology.1996
8Packer M,Colucci WS,Sackner Bernstain JD,et al.Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure[].Circulation.1996
9Krum H,Sackner Bernstain JD,Goldsmith RL,et al.Double-blind, placebo-controlled study of the longterm efficacy of carvedilol in patients with severe chronic heart failure[].Circulation.1995
